Treatment of Retroperitoneal Fibrosis in IgG4-Related Disease with Ureteral Obstruction
This protocol addresses idiopathic retroperitoneal fibrosis occurring in the context of IgG4-related disease (IgG4RD), where ureteral obstruction is a key complication requiring both urological and systemic management.
Clinical scenario
Most idiopathic retroperitoneal fibrosis is now considered part of the IgG4-related disease spectrum. When ureteral obstruction is present, management must address both the obstruction and the underlying inflammatory process. Serum IgG4 levels serve as an important guide throughout treatment. Long-term therapy is typically required, as the disease can relapse and lead to organ dysfunction after treatment is discontinued.
Treatment approach
Initial management addresses ureteral obstruction through urinary drainage — either via stenting or percutaneous means. This is followed by a corticosteroid-based regimen in which the dose is guided by serial serum IgG4 monitoring, with a structured induction phase followed by gradual tapering toward long-term maintenance.
The full protocol details the specific induction dose, tapering schedule, maintenance targets, and monitoring intervals — access it below.
Clinical goals
- Suppression of serum IgG4 to guide dosing and assess response
- Reduction of retroperitoneal plaque on imaging
- Resolution of ureteral obstruction and restoration of renal function
References
DOI: 10.1111/iju.14218
- Currently, most idiopathic RPF is considered to be a part of this disease spectrum.
- In IgG4RD, the serum IgG4 level is helpful to control the dosage of glucocorticoid.
- Generally, in idiopathic RPF causing ureteral obstruction, a good outcome for renal function is expected, although long-term steroid therapy along with urinary drainage is often required.
- At first, ureteral obstruction is usually conservatively managed with ureteral stenting or PNS.
- The treatment is usually initiated with 0.6–1 mg/kg/day of PSL for 2–4 weeks; then the dosage is gradually tapered and maintained with 2.5–5 mg/day for >6 months.
- In typical IgG4RD, long-term maintenance with 2.5–5 mg of PSL is necessary, because the disease is likely to relapse, leading to involved organ dysfunction after discontinuation of the treatment.
- Maintain the dose suppressing serum IgG4 with assessment by annual radiographic examinations.
- The goal of treatment for retroperitoneal fibrosis should be freedom from the stent/nephrostomy with withdrawal of the glucocorticoid in addition to salvage of renal function; however, conservative management does not always provide favorable outcomes.
View source ↗